Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Today in Healthcare.
Press releases published on April 22, 2025
U.S. Oral Surgery Management Announces Partnership with Douglas J. Valentine DDS Oral & Maxillofacial Surgery
GlobeNewswire
·
April 22, 2025
IRVING, Texas and GRASS VALLEY, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Management services organization U.S. Oral Surgery Management (USOSM) has secured a new partnership with Douglas J. Valentine DDS Oral …
BioProcess360 Partners Launches New Chromatography Company Through Transfer of IP, Assets and Personnel from LigaTrap Technologies
GlobeNewswire
·
April 22, 2025
RALEIGH, N.C., April 22, 2025 (GLOBE NEWSWIRE) -- BioProcess360 Partners today announced the formation of ChromaGenix, a new biotechnology company focused on advancing downstream purification technologies for emerging biotherapeutics. The company has been …
BioProcess360 Partners gründet neues Chromatographie-Unternehmen durch Transfer von IP, Vermögenswerten und Personal von LigaTrap Technologies
GlobeNewswire
·
April 22, 2025
RALEIGH, North Carolina, April 22, 2025 (GLOBE NEWSWIRE) -- BioProcess360 Partners gab heute die Gründung von ChromaGenix bekannt, einem neuen Biotechnologieunternehmen, das sich auf die Entwicklung nachgeschalteter Aufreinigungstechnologien für neue …
Trethera To Participate in Panel Discussion and Research Poster Competition At Los Angeles Bioscience Ecosystem Summit 2025
GlobeNewswire
·
April 22, 2025
LOS ANGELES, April 22, 2025 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune diseases, announces a forthcoming panel discussion and poster …
Nerve Freedom Reviews [Investigated Complaints] Nerve Alive Best Neuropathy Supplement for Nerve Pain Relief Naturally
GlobeNewswire
·
April 22, 2025
LAKELAND, Fla., April 22, 2025 (GLOBE NEWSWIRE) -- Introduction to Nerve Freedom! Nerve Pain often referred to as neuropathy — is one of the most frustrating and debilitating conditions a person can endure. Whether it manifests as a tingling sensation, …
Babesiosis Disease Burden in United States is Substantially Higher Than Official Estimates, According to Preliminary Results of 60 Degrees Pharma Survey
GlobeNewswire
·
April 22, 2025
In a survey representative of the general U.S. adult population, 1.26 percent of respondents – equivalent to about 3 million people – reported having received a medical diagnosis of babesiosis during their life-time; CDC data imply only about 73,000 people …
科兴控股生物技术有限公司管理层关于审计师辞职的声明
GlobeNewswire
·
April 22, 2025
北京, April 22, 2025 (GLOBE NEWSWIRE) -- 致科兴控股生物技术有限公司全体股东及各利益相关方： 科兴控股生物技术有限公司（纳斯达克股票代码：SVA，以下简称 “公司”）的管理层近日收到公司外部审计师的通知，审计师已决定辞去公司2024 财年年终审计师职务。 根据审计师的辞职信，审计师的辞职决定源于公司现任董事会于2025年4月1 …
Tarsus to Present Several Scientific Abstracts Highlighting the Global Prevalence of Demodex Blepharitis and the Clinical Impact of XDEMVY at the American Society of Cataract and Refractive Surgery (ASCRS) 2025 Annual Meeting
GlobeNewswire
·
April 22, 2025
IRVINE, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) will present four distinct data sets highlighting the global prevalence and real-world patient burden of Demodex blepharitis, as well as the impact of XDEMVY® ( …
AP Biosciences Doses First Patient in Phase 1/2 Clinical Trials of AP402 for HER2+ Cancer Patients
GlobeNewswire
·
April 22, 2025
TAIPEI, Taiwan, April 22, 2025 (GLOBE NEWSWIRE) -- AP Biosciences, a clinical-stage biopharmaceutical company dedicated to transforming cancer therapy through development of innovative bispecific antibodies, today announced that it has dosed the first …
US Healthcare Analytics Market worth US$47.40 billion by 2029 with 24.5% CAGR | MarketsandMarkets™.
GlobeNewswire
·
April 22, 2025
Delray Beach, FL, April 22, 2025 (GLOBE NEWSWIRE) -- The global US Healthcare Analytics Market, valued at US$15.84 billion in 2024, is forecasted to grow at a robust CAGR of 24.5%, reaching US$47.40 billion by 2029. The major factors driving the market …
Day One to Report First Quarter 2025 Financial Results Tuesday, May 6, 2025
GlobeNewswire
·
April 22, 2025
BRISBANE, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life- …
Rakovina Therapeutics Congratulates Scientific Advisor Dr. Artem Cherkasov on Global Recognition for Breakthrough AI Innovation in Drug Discovery
GlobeNewswire
·
April 22, 2025
VANCOUVER, British Columbia, April 22, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered drug discovery, is pleased to …
The Best Natural Testosterone Booster Supplements For Men:~ Honest Customer Reviews 2025
GlobeNewswire
·
April 22, 2025
NEW YORK, April 22, 2025 (GLOBE NEWSWIRE) -- Low testosterone levels can cause many problems in men, such as less muscle, less energy, less libido and low mood. You may want to find a solution, but you don’t know which products are good and which are bad. …
BlueGenes Partners with Level Care to Revolutionize Medication Management for Union Members
GlobeNewswire
·
April 22, 2025
SCOTTSDALE, Ariz., April 22, 2025 (GLOBE NEWSWIRE) -- BlueGenes, a pioneering technology company specializing in permission medicine, today announced a strategic partnership with Level Care, the healthcare division of the carpenters union. This …
Theranica Announces Coverage Policy from the Second Largest U.S. Health Insurer for Its Nerivio® REN Wearable Migraine Treatment, Reaching Access for 80 Million Americans
GlobeNewswire
·
April 22, 2025
BRIDGEWATER, N.J. and NETANYA, Israel, April 22, 2025 (GLOBE NEWSWIRE) -- Theranica, a prescribed neuromodulation therapeutics company, today announced that that its FDA-cleared, non-drug, prescribed migraine treatment, the Nerivio® REN wearable, is now …
SCIENTURE announces manufacturing and supply chain readiness for ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL for a target product launch in July 2025.
GlobeNewswire
·
April 22, 2025
TAMPA, FL, April 22, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through …
Daxor Corporation to Exhibit at the 45th International Society for Heart and Lung Transplant (ISHLT) Annual Meeting and Scientific Sessions
GlobeNewswire
·
April 22, 2025
Daxor Brings Advanced Blood Volume Analysis Solutions to Elite Heart and Lung Transplantation Forum Oak Ridge, TN, April 22, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, will attend the …
MBX Biosciences to Participate in Citizens and RBC May Investor Conferences
GlobeNewswire
·
April 22, 2025
CARMEL, Ind., April 22, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic …
Cronos Unveils New Spinach® 1.2g Vapes and SOURZ by Spinach® Gummies Enhanced with Rare Cannabinoids
GlobeNewswire
·
April 22, 2025
TORONTO, April 22, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc.’s (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) best-selling cannabis brand, Spinach®, is thrilled to introduce three all-new 1.2g vape products, each expertly crafted with premium THC …
FluidForm Bio™ Strengthens IP Portfolio with Newly Issued Patent on Key Aspects of its Proprietary FRESH™ Platform
GlobeNewswire
·
April 22, 2025
WALTHAM, Mass., April 22, 2025 (GLOBE NEWSWIRE) -- FluidForm Bio™, a leader in cell therapies for chronic diseases such as type 1 diabetes, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,215,202 B2, …